Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? an European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study.
Fabio Zattoni,Giancarlo Marra,Alberto Martini,Veeru Kasivisvanathan,Jeremy Grummet,Timothy Harkin,Guillaume Ploussard,Jonathan Olivier,Peter K. Chiu,Massimo Valerio,Alessandro Marquis,Paolo Gontero,Hongqian Guo,Junlong Zhuang,Mark Frydenberg,Daniel Moon,Alessandro Morlacco,Alexander Kretschmer,Francesco Barletta,Isabel Heidegger,Derya Tilki,Roderick van den Bergh,Fabrizio Dal Moro,Alberto Briganti,Francesco Montorsi,Giacomo Novara,Giorgio Gandaglia
DOI: https://doi.org/10.1016/j.euf.2023.01.016
IF: 5.952
2023-01-01
European Urology Focus
Abstract:Background: The concordance rates of transperineal (TP) versus transrectal (TR) pros-tate biopsies with radical prostatectomy (RP) specimen have been assessed poorly in men diagnosed with magnetic resonance imaging (MRI)-targeted biopsy (TBx).Objective: To evaluate International Society of Urological Pathology (ISUP) concordance rates between the final pathology at RP and MRI-TBx or MRI-TBx + random biopsy (RB) according to the biopsy approach.Design, setting, and participants: A multi-institutional database included patients diag-nosed with TP or TR treated with RP. Intervention: TP-TBx or TR-TBx of the prostate.Outcome measurements and statistical analysis: The ISUP grade at biopsy was compared with the final pathology. A multivariable logistic regression analysis (MVA) was per-formed to assess the association between the biopsy approach (TP-TBx vs TR-TBx) and ISUP upgrading, downgrading, concordance, and clinically relevant increase (CRI). Results and limitations: Overall, 752 (59%) versus 530 (41%) patients underwent TR ver-sus TP. At the MVA, TP-TBx was an independent predictor of upgrading (odds ratio [OR] 0.6, 95% confidence interval [CI] 0.4-0.9, p < 0.01) and improved concordance relative to the final pathology (OR 1.7, 95% CI 1.2-2.5, p < 0.01) after adjusting for age, cT stage, Prostate Imaging Reporting and Data System, number of targeted cores, prostate -specific antigen, and prostate volume. Moreover, TP-TBx was associated with a lower risk of CRI than TR-TBx (OR 0.7, p < 0.01). This held true when considering patients who underwent MRI-TBx + RB (OR 0.6, p < 0.01). The inclusion of men who had RP rep-resents a potential selection bias.Conclusions: The adoption of TP-TBx compared with TR-TBx may reduce the risk of upgrading and improve the concordance of biopsy grade with the final pathology. The TP approach decreases the odds of CRI with improved patient selection for the correct active treatment. Patient summary: In this report, we evaluated whether transperineal (TP) targeted biopsy (TBx) may improve the concordance of clinically significant prostate cancer with the final pathology in comparison with transrectal (TR) TBx in a large worldwide popu-lation. We found that TP-TBx might increase concordance compared with TR-TBx. Adding random biopsies to target one increases accuracy; however, concordance with the final pathology is overall suboptimal even with the TP approach.& COPY; 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.